Niaspan Reverse Payment Antitrust Litigation

Court: United States District Court, Eastern District of Pennsylvania

Case No.: 13-md-2460

Leadership Position: Interim Co-Lead Counsel

WBE is Interim Co-Lead Counsel for the end purchaser plaintiffs in an antitrust class action against AbbVie Inc. and Teva Pharmaceuticals USA, Inc. (and related companies) involving the cholesterol drug Niaspan.  The plaintiffs allege that the defendants conspired to keep a generic version of Niaspan off the market for more than eight years.  The plaintiffs have also alleged that the defendants’ conduct caused consumers and drug benefit plans to pay more for Niaspan and its generic equivalents than they otherwise would have, in violation of state antitrust and consumer protection laws.

To view a copy of the consolidated class action complaint, click here.

News Articles

WBE Ranked in Chambers & Partners 2026 USA Spotlight

WBE is proud to announce the firm has been ranked for the second year by Chambers & Partners in their Spotlight Illinois guide. WBE was recognized for our work in General Litigation, and is ...

Court Grants Final Approval of $2.25 Million Settlement in Effexor XR Antitrust Litigation

On Tuesday, August 19, 2025, United States District Judge Zahid N. Quraishi of the District of New Jersey granted final approval of Indirect Purchaser Plaintiffs’ $2.25 million class-action ...

Court Grants Plaintiffs’ Motion for Summary Judgment in Part in Actos Antitrust Litigation

On Monday, March 31, 2025, U.S. District Court Judge Ronnie Abrams of the Southern District of New York partially granted summary judgment to two classes of Plaintiffs who purchased the diabetes ...